Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA consumer warning

This article was originally published in The Tan Sheet

Executive Summary

The dietary supplements Emagrece Sim and Herbathin should not be used and should be returned to suppliers because they "may contain several active ingredients, including controlled substances, found in prescription drugs that could lead to serious side effects or injury," the agency announces Jan. 13. FDA has issued an import alert to prevent importation of the products, which are made in Brazil by the firms Fitoterapicos and Phytotherm Sim. The products contain fluoxetine HCl (Prozac) and chlordiazepoxide HCl (Librium), which are used to relieve anxiety, according to FDA. They also were found to contain Fenproporex, a stimulant that is "not approved for marketing in the U.S." and is converted in the body to amphetamine. The supplements are sold on the Internet, and FDA is "aware of commercial imports of these products and individuals importing them for personal use"...

You may also be interested in...



HBW Product Launches: Preminity, Dr. Formulated, Clear Focus, Zicam Immune, Synergy Plus

Garden of Life offers Triple Action Dr. Formulated; BasicBites Synergy Plus for oral care; Zicam extends to Daily Immune Support and Sleep + Immune Support with melatonin; Novastell launches Preminity for PMS; Prunelax in gummy; and lion’s mane mushroom in Clear Focus.

Medicare Price ‘Negotiation’ : Manufacturer Compliance Gets Tougher Enforcement Provision

As legislation authorizing Medicare price 'negotiation' clears the Senate and appears on its way toward enactment after years of efforts by US congressional Democrats, and opposition by Republicans and the pharmaceutical industry, the bill continues to be tweaked.

Senate Budget Draft Would Be Less Generous To US FDA Than House For FY2023

Senate appropriations bill would take back some of increase House offered Center for Drug Evaluation and Research and other FDA programs, setting up negotiations as start of FY2023 nears.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS099002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel